For this purpose, Sobi has prepared a base prospectus, which has today been approved and registered by the
SEB has been appointed arranger of the MTN Programme and will also act as dealer together with
Sobi
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
Head of Investor Relations
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-establishes-mtn-programme-with-a-framework-amount-of-sek-10-billion--publishes-a-base-prospectu,c3967938
https://mb.cision.com/Public/14266/3967938/8569aff3444d55ac.pdf
(c) 2024 Cision. All rights reserved., source